SGLT2 inhibitor downregulates ANGPTL4 to mitigate pathological aging of cardiomyocytes induced by type 2 diabetes.

Yun Wen, Xiaofang Zhang, Han Liu, Haowen Ye, Ruxin Wang, Caixia Ma, Tianqi Duo, Jiaxin Wang, Xian Yang, Meixin Yu, Ying Wang, Liangyan Wu, Yongting Zhao, Lihong Wang

Department of Endocrinology and Metabolism, First Affiliated Hospital of Jinan University, Guangzhou, China. · pubmed

Paper

Abstract

Senescence is recognized as a principal risk factor for cardiovascular diseases, with a significant association between the senescence of cardiomyocytes and inferior cardiac function. Furthermore, type 2 diabetes exacerbates this aging process. Sodium-glucose co-transporter 2 inhibitor (SGLT2i) has well-established cardiovascular benefits and, in recent years, has been posited to possess anti-aging properties. However, there are no reported data on their improvement of cardiomyocytes function through the alleviation of aging. Consequently, our study aims to investigate the mechanism by which SGLT2i exerts anti-aging and protective effects at the cardiac level through its action on the FOXO1-ANGPTL4 pathway.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper investigates the mechanism by which SGLT2 inhibitors may exert anti-aging effects on cardiomyocytes, addressing a potential root cause of aging-related cardiac dysfunction in the context of type 2 diabetes. While it presents solid research on a relevant topic, the findings appear to be an incremental advance rather than a major breakthrough, limiting its overall impact in the field of longevity research.

Author of this paper? Send a correction.